Viloxazine ER (Qelbree <sup>®</sup> ): A New Non-Stimulant Option in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Viloxazine ER (Qelbree ^® ): A New Non-Stimulant Option in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder

Published:2022-07 Issue:7 Volume:60 Page:7-9
ISSN:0279-3695
Container-title:Journal of Psychosocial Nursing and Mental Health Services
language:en
Short-container-title:J Psychosoc Nurs Ment Health Serv

Author:

Kameg Brayden

Abstract

The current article provides a brief overview for psychiatric–mental health nurse practitioners of viloxazine extended-release (Qelbree ® ) for the treatment of pediatric attention-deficit/hyperactivity disorder. [ Journal of Psychosocial Nursing and Mental Health Services, 60 (7), 7–9.]

Publisher

SLACK, Inc.

Subject

Pshychiatric Mental Health,General Nursing

Reference19 articles.

1. ED4 Economic Burden of Attention-Deficit/Hyperactivity Disorder (ADHD) Among Children and Adolescents in the United States (US): A Societal Perspective

2. Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication

3. Morbidities and mortality of diagnosed attention deficit hyperactivity disorder (ADHD) over the youth lifespan: A population‐based retrospective cohort study

4. Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder

5. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP